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What this paper adds 
 
What is already known - 
The evaluation of psychotropic drug effects has been conducted utilising 
psychometric test batteries to assess changes in daytime cognition and 
psychomotor functioning and PSG to assess changes in sleep. Actigraphy is 
widely accepted as a non-invasive tool for assessing sleep-wake patterns in 
different groups. However, there is limited data to show that actigraphy can 
reliably measure the daytime and night-time characteristics of a CNS drug.   
 
What this study adds - 
This study provides further evidence that actigraphy is sensitive not only to the 
sedating effects of a hypnotic drug but also to the hangover effects of the drug 
the following morning. It confirms that the actiwatch is able to detect the 
effects of a hypnotic on actigraphically measured sleep. Further evidence that 
actigraphy can provide a reliable and sensitive indication of the time course of 
action of psychoactive drugs. 
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ABSTRACT 
Aim: To assess whether actigraphy is sensitive to lorazepam-induced 
changes in cognitive and psychomotor performance by measuring activity 
levels following placebo and lorazepam (LZP) dosing. 
Methods: Healthy volunteers were randomised to a double-blind, placebo-
controlled, crossover trial. Activity was recorded by actigraphy throughout 
each test period and pooled into 30 min bins for analysis. Following LZP 
dosing (2.5 mg at 18.00 h) psychomotor and cognitive tests were conducted 
at regular intervals. 
Results: Activity levels were significantly reduced between the psychometric 
tests (P < 0.02) at 2, 3 and 5 h post dose and during the psychometric tests (P 
< 0.02) at 2.5 and 4.5 h post dose. Subjects only felt sedated (P < 0.01) at 4.5 
h post dose. Activity levels were also significantly reduced (P < 0.05) during 
sleep (23:00-07:00 h), and the following morning, activity levels remaining 
suppressed (P < 0.02) at 13.5 and 14 h post dose. Cognitive and 
psychomotor performance reflected changes in activity levels with significant 
impairment (P < 0.05) at 2.5, 3.5, 4.5 and 14.5 h post dose.  
Conclusion: This study showed that actigraphic activity levels were 
significantly reduced following LZP dosing. These changes were mirrored by 
impairment of cognitive and psychomotor performance. Actigraphy is 
therefore sensitive to the sedating effect of LZP and appears able to detect 
changes in sleep behaviour (hypnotic efficacy) and residual effects the 
following morning. Actigraphy may thus be a useful tool in assessing the 
psychopharmacology of CNS medication. 
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Introduction 
 
The development of actigraphy has allowed rest-activity patterns to be 
measured in difficult population groups. Whilst polysomnography (PSG) 
remains the gold standard for assessing sleep, actigraphy has offered a 
cheaper, less invasive alternative, which has the added advantage of being 
able to monitor rest and activity patterns for longer periods of time in situations 
where an intensive in-house assessment would be difficult. 
 
Actigraphy is widely accepted as a non-invasive tool for assessing sleep-wake 
patterns in different groups [1-3], including insomnia [4,5], sleep-related 
breathing [6], children [7], restless legs [8], depression [9, 10] and circadian 
rhythm disorders [11]. There is limited data, however, to show that actigraphy 
can reliably measure the daytime and night-time characteristics of a CNS 
drug. Whether actigraph technology is sensitive to the sedating effects of 
medication and how accurately actigraphy is able to track drug 
pharmacokinetics and pharmacodynamics remains to be determined.  
 
Currently the evaluation of psychotropic drug effects has been conducted 
utilising psychometric test batteries to assess daytime cognition and 
psychomotor functioning [12-14] whilst night-time sleep has been evaluated 
with PSG to assess changes in sleep architecture. This design is possible in 
Phase I and II studies but the data are limited to a relatively small number of 
volunteers and may not be relevant to the general population and in particular 
to the patient groups intended to receive the medication. Although it is not 
economical or logistically possible to conduct comprehensive in-house 
Lorazepam-induced reduction in activity 
6 
assessments in Phase III studies, actigraphy may be of use in the assessment 
of drug-induced changes in night-time sleep and in daytime activity in large 
scale patient studies. Changes in daytime activity levels may reflect increased 
sedation – a common side effect of some centrally acting compounds. 
Psychometric assessments have shown that a number of cognitive functions 
are adversely affected by increased sedation including information 
processing, memory and attention [15-17]. 
 
Previous research has assessed the effect of drugs on actigraphic sleep and 
daytime behaviour in small scale studies including sedatives [18,19], anti-
depressants [13,20,21], hypnotics [22,23], antihistamines [24-26] and 
stimulants [27]. The classes of drugs which are prescribed for inducing sleep, 
reducing anxiety or reducing a histaminic response have well documented 
side effects including reduction in activity during wake [22,23] and impairment 
of mental ability and alertness in the acute phase following drug administration 
[28,29]. Drug-induced reduction in activity has been studied in ‘spontaneous’ 
activity [29] and there are some data to suggest that actigraphy is able to 
detect “hangover effects” [18,22,28,30-33]. These studies, however, have 
employed different actigraphs and not the Actiwatch® (Cambridge 
Neurotechnology Ltd., UK) which has been used in this present study. There 
are important differences between these devices and the algorithms they 
deploy which means that confirmatory studies using the actiwatch are 
required to assess the utility of ‘actigraphy’ as a tool in psychopharmacology. 
 
LZP, a hypnotic benzodiazepine, is prescribed to alleviate anxiety and aid 
sleep. LZP is usually prescribed in small doses (1 mg) during the day to 
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reduce anxiety and is also given in a single dose at night (2.5 mg) to initiate 
sleep. It is readily absorbed reaching a peak concentration approximately 2 h 
after dosing with an elimination half life of about 12 h [34]. A dose of 2.5 mg 
LZP has been shown to increase total sleep time and change sleep 
architecture at night [35,36], induce subjective daytime sleepiness [37], and 
reduce anxiety symptoms [38]. Previous studies have also shown that it 
impairs daytime psychomotor performance and memory [39]. Studying a 
hypnotic known to produce performance impairment such as LZP provides a 
useful tool to assess changes in motor activity in association with changes in 
both cognitive and psychomotor performance. 
 
The aim of the present study was thus to evaluate the effect of a single dose 
(2.5 mg) of LZP, compared with placebo, on actigraphically assessed motor 
activity in healthy volunteers. The ability of actigraphy to detect LZP-induced 
changes in both spontaneous and controlled activity was assessed. In 
addition, whether actigraphy could distinguish changes in the sleep profile and 
any hangover effect of the drug was also determined.  
 
Methods 
Study Design 
Volunteers were randomised to a double-blind, placebo-controlled, crossover 
design study where each volunteer acted as their own control. The data 
presented here were taken from a larger clinical trial and for the purpose of 
this investigation only the results of the study treatments of placebo and LZP 
are presented. Volunteers received either LZP (2.5 mg) or placebo on two 
consecutive days, in a Latin Square design so that each volunteer received 
Lorazepam-induced reduction in activity 
8 
each treatment. All treatments were supplied in identical capsules and each 
oral dose was taken at 18:00 h on Day 2 and Day 3 of each study period. 
Each of the study periods was separated by a six day washout.  
 
Subjects 
Twenty four healthy male and female Caucasian volunteers were recruited 
onto the study of which 21 subjects (10 males, 11 females) completed both 
the study treatments. The mean (± SD) age of the 21 subjects was 27.2 ± 5.4 
years and the mean height, weight and body mass index (BMI) of the subjects 
at screening were 1.70 ± 0.10 m, 69.2 ± 9.4 kg and 23.7 ± 2.2 kg/m2, 
respectively. 
 
All participants were in good health without any clinical history of physical or 
mental illness as assessed by a physician. No subjects were taking any 
concomitant medication (except oral contraceptives) likely to interfere with the 
study measures. Following a medical history, subjects underwent a medical 
examination (including 12-lead electrocardiogram, urinalysis, haematology, 
biochemistry, alcohol breath test and drugs of abuse screen). Written 
informed consent was obtained from all volunteers together with the consent 
of their medical practitioner to participate in the trial. The study was approved 
by the Ethics Committee of the South West Surrey Health Authority.  
 
Volunteers were instructed to avoid late-nights and adhere to their usual 
bedtime (minimum 6-8 h sleep) before each of the study periods. In order to 
ensure compliance they were required to wear actigraphs continuously from 
the screening visit to study completion (maximum 8 weeks). The use of 
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alcohol, nicotine and products containing caffeine were prohibited for 24 h 
before and on study days.  
 
Study Procedure 
Volunteers attended the Unit on Day 1 where a breath alcohol reading was 
taken and a urine sample obtained for drugs of abuse screening. The 
actigraph was removed, downloaded, reattached and checked for sleep wake 
compliance. Volunteers were familiarised with the study procedures and 
trained on the standard battery of psychometric tests (as described below) at 
the start of the trial in order to minimize learning effects during the study [40].  
 
The psychometric test battery was performed at 07:00 h on Day 2 of each 
study period in order to obtain pre-treatment baseline recordings. Treatment 
(placebo or LZP) was administered at 18:00 h. After dosing the standard 
battery of psychomotor and cognitive tests was conducted at 1, 2, 3, 4 and 14 
h post dose. During the study periods food consumption was strictly controlled 
and mealtimes were regulated, breakfast was consumed at 09:00 h; lunch at 
12:00 h; a snack at 16:00 h; and dinner at 20:00 h on Day 1 and at 17:45 h on 
Day 2 and Day 3. 
 
Bedtime (subjects supine in the dark in a standardised controlled 
environment) was from 23:00-07:00 h and volunteers were prevented from 
napping during the day. Blood samples were taken hourly at 15 min past the 
hour from 18:00-22:00 h on Day 3 to assess the pharmacokinetic profile of the 
drug (data not shown). 
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Actigraphy 
Volunteers were required to wear Actiwatches AW4 (Cambridge 
Neurotechnology Ltd., UK) on their non-dominant wrist for the duration of 
each study period (4 days), to monitor rest and activity. Actigraphy records 
activity in counts per epoch so drug-induced changes in activity may be 
observed and measured. Actiwatches were also worn from the screening visit 
to the start of the study (up to 30 days) and during the washout period of at 
least 6 days between each study period to ensure volunteer compliance and 
maintenance of a regular bedtime.  
 
Activity was automatically calculated using the Sleepwatch® software (version 
1.8) and its validated sleep/wake algorithm was used to calculate the amount 
of sleep-like activity, by scoring each individual epoch as sleep or wake, as 
well as various associated sleep parameters. The Actiwatch was set at the 
manufacturer’s default setting and activity was captured in 1 min epochs. The 
mean activity for each 30 min time interval was calculated from dosing at 
18:00 h for 24 h. Each 30 min period before the psychometric tests was 
classified as “spontaneous activity” and each 30 min period during which the 
tests were performed was classified as “controlled activity”. Data were 
captured electronically. 
 
Cognitive and Psychomotor Function 
Cognitive and psychomotor performance was measured in a 30 min test 
battery, which included Choice Reaction Time - HICKS (H-CRT); Continuous 
Tracking Task (CTT) and Line Analogue Rating Scales (LARS). These tests 
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are known to be sensitive to the impairing effects of psychotropic compounds 
[12,36].  
 
Choice Reaction Time – HICKS (HCRT) 
The Hick’s CRT task is a measure of sensorimotor performance [41,42].  
Volunteers were required to extinguish 1 of 6 equidistant red lights, illuminated 
at random, by touching the associated response button. The mean total 
reaction time (TRT) was measured as the sum of the recognition reaction time 
(RRT), the cognitive component, and the motor reaction time (MRT), the 
psychomotor component. All data were captured electronically. 
 
Continuous Tracking Task (CTT) 
This test is a divided attention interactive task of psychomotor performance 
[43-45]. Volunteers were required to keep a cursor in alignment with a moving 
target on a computer screen using a mouse, whilst simultaneously responding 
to a peripheral stimulus. The response measure of the tracking component of 
the task was the mean deviation in pixels, with lower scores indicative of more 
accurate tracking (CTT-ER). The mean reaction time in milliseconds was 
taken as the response measure of the peripheral awareness task (PRT) 
component. All data were captured electronically. 
 
Subjective Evaluation 
The Line Analogue Rating Scale (LARS) [14,46] was employed as a measure 
of the subjective effect of the medication. Volunteers were required to indicate 
their present feeling, where the mid-point on a 10 cm scale represented their 
normal state of mind before treatment began. LARS was performed on Day 2 
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at 07:00 h; 17:00 h; 19:00 h; 20:00 h; 21:00 h and 22:00 h and then on Day 3 
at 08:00 h. The mean scores of ratings of the ‘tiredness’, ‘drowsiness’ and 
‘alertness’ factors were taken as a measurement of perceived sedation. 
  
Statistical Analysis 
 
Two way ANOVA was performed on the activity and psychometric data with 
time post dose and treatment as factors using PROC MIXED of SAS (Version 
8.2). Post hoc tests were used to determine which times post dose were 
significantly different between drug and placebo. 
 
Results 
 
Activity  
 
There was a significant effect of treatment on ‘spontaneous’ activity at 2 
(F(1,1057) = 5.88, P < 0.05), 3 (F(1,1258) = 35.82, P < 0.0001) and 5 h (F(1,1296) = 
6.07, P < 0.05) after dose with LZP significantly reducing activity compared to 
placebo. In addition, LZP significantly reduced ‘controlled’ activity during the 
psychometric tests at 2.5 (F(1,1229) = 15.16, P < 0.01) and 4.5 h (F(1,1283) = 
15.94, P < 0.0001) post dose. Due to missing data, where some subjects 
removed the actigraph, the denominator degrees of freedom in the quoted ‘F’ 
ratio varied from one analysis to another. The overall effect of drug on activity 
is shown in Figure 1a. There was also a significant effect of LZP on 
‘spontaneous’ activity immediately following the 8 h sleep period which 
occurred at 5-13 h post dose. Compared to placebo, LZP produced a 
significant reduction in spontaneous activity in the hour after waking, at 13.5  
(F(1,1296) = 5.66, P < 0.05) and 14.0 h (F(1,1287) = 8.19, P < 0.01) post dose. In 
contrast there was no significant effect of LZP on controlled activity at 14.5 h 
post dose (Figure 1a). 
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Following a second dose of LZP on Day 3, the drug produced a similar 
significant reduction in activity at 2 (F(1,1016) = 12.64, P < 0.01), 2.5 (F(1,1171) = 
24.48, P < 0.0001), 3 (F(1,1200) = 37.16, P < 0.0001), 4.5 (F(1,1224) = 28.91, P < 
0.0001) and 5 h (F(1,1237) = 8.23, P < 0.01) post dose (Figure 1b). LZP again 
produced a significant reduction in activity immediately following the 8 h sleep 
period at 14 h (F(1,1228) = 7.24, P < 0.05) post dose compared to placebo. 
 
Figure 1 
 
Activity was also continuously monitored during the sleep periods (23:00 – 
07:00 h). On night 2, LZP produced a significant reduction in activity at the 
beginning and at the end of the sleep period at 5.5 (F(1,1296) = 5.12, P < 0.05), 
7.5 (F(1,1296) = 4.18, P < 0.05), 10.5 (F(1,1296) = 4.17, P < 0.05), and 12.5 h 
(F(1,1296) = 5.70, P < 0.05) post dose compared to placebo (Figure 2a). A 
similar effect of LZP was observed on activity levels during the sleep period 
on night 3, a significant reduction in activity again being noted at 5.5 (F(1,1237) = 
11.31, P < 0.001), 7.5 (F(1,1237) = 7.81, P < 0.01), 9.5 (F(1,1237) = 10.46, P < 
0.01), 10.5 (F(1,1237) = 9.10, P < 0.01), 12 (F(1,1237) = 3.92, P < 0.05), 12.5 
(F(1,1237) = 7.20, P < 0.01) and 13.0 h (F(1,1237) = 4.79, P < 0.05) post dose 
compared to placebo (Figure 2b). 
Figure 2 
‘Sleep-like’ minutes 
Each individual epoch was scored as sleep or wake, and ‘sleep-like activity’ 
was pooled into 30 min bins. Although there was an increase in the number of 
sleep-like epochs overall during the 5 h period following LZP administration, 
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this was not statistically significant (Figure 3). However, there was a 
significant increase in ‘sleep-like’ minutes during ‘spontaneous’ activity at 4 h 
post dose (F(1,20) = 4.28, P = 0.0517). 
Figure 3 
Sleep parameters 
The effect of LZP on various actigraphically-derived sleep parameters is 
shown in Table 1. Compared to placebo, LZP produced a significant reduction 
in the number of wake bouts (F(1,20) = 6.59, P < 0.05), the number of immobile 
phases (F(1,20) = 5.92, P < 0.05), percentage time moving (F(1,20) = 5.41, P < 
0.05), mean activity score (F(1,20) = 5.20, P < 0.05), actual wake time (F(1,20) = 
6.71, P < 0.05) and the fragmentation index (F(1,20) = 5.10, P < 0.05) on the 
first night after dosing. LZP significantly increased actual sleep percent (F(1,20) 
= 7.22, P < 0.05), percentage time immobile (F(1,20) = 5.41, P < 0.05), mean 
length immobility (F(1,20) = 8.76, P < 0.01) and mean sleep bout time (F(1,20) = 
8.13, P < 0.01). 
 
Similarly on the second night after dosing LZP reduced activity shown as a 
significant reduction in the percentage time moving (F(1,19) = 9.09, P < 0.01), 
percentage time immobile (F(1,19) = 9.09, P<0.01) and in the number of 
minutes moving (F(1,19) = 8.4, P < 0.01). LZP also significantly increased 
actual sleep percent (F(1,19) = 6.58, P < 0.05) and actual wake time (F(1,19) = 
6.21, P < 0.05) (Table 1). 
Table 1 
The subjective evaluation of sedation was measured with LARS by combining 
the scores for ‘tired’, ‘drowsy’ and ‘alert’. LZP caused a significant increase in 
subjective reports of sedation at 4.5 h post dose only (F(1,20) = 10.72, P < 0.01) 
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(Figure 4a). The objective assessment of sedation was measured with the 
psychometric tests. Analysis of the total reaction time (TRT) component of the 
CRT task revealed that LZP also caused a significant increase in TRT at 2.5 
(F(1,21) = 9.07, P < 0.01), 3.5 (F(1,20) = 6.51, P < 0.05), 4.5 (F(1,20) = 9.75, P < 
0.01) and 14.5 h (F(1,20) = 12.61, P < 0.01) post dose compared to placebo 
(Figure 4b). LZP also caused a significant increase in response time to the 
peripheral stimulus component of the CTT at 2.5 (F(1,21) = 9.65, P < 0.01), 3.5 
(F(1,20) = 13.74, P < 0.01), 4.5 (F(1,20) = 10.14, P < 0.01) and 14.5 h (F(1,20) = 
5.09, P < 0.05) post dose compared to placebo (Figure 4c). Analysis revealed 
that LZP also significantly affected tracking accuracy by increasing the error 
component (CTT-ERR) at 2.5 (F(1,21) = 6.58, P < 0.05), 3.5 (F(1,20) = 6.84, P < 
0.05), 4.5 (F(1,20) = 8.33, P < 0.01), and 14.5 h (F(1,20) = 6.98, P < 0.05) post 
dose compared to placebo (Figure 4d). 
Figure 4 
Discussion 
It has been shown that reduced behavioural activity detected by actigraphy is 
reflected in both the psychometric and subjective assessment of sedation, 
psychomotor performance, general information processing skills and arousal 
(20,21). The effects of LZP on the CNS and in particular the impairment of 
psychomotor function are well documented [39] so it provided a useful base 
on which to evaluate the ability of actigraphy to detect changes in activity 
patterns during the acute phase after a drug dose in relation to changes in 
psychomotor function. 
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There is relatively little literature on the actigraphic profile of drugs. Whilst 
some authors [22,24,29] have reported that the derived actigraph data show 
significant reductions in activity after dosing with various compounds, a variety 
of times blocks have been used ranging from 6 to 24 h. Although this has 
provided an indication that actigraphy may be able to detect changes in 
behavioural activity due to the effects of medication, the use of these large 
analysis time frames may not be sufficient to provide a discrete profile of the 
drug and of its time course of effect on activity and pharmacodynamics. A 
study on the effects of several antihistamines in comparison to placebo [33], 
however, has provided evidence that by using the AMI 32 actigraph 
(Ambulatory Monitoring Inc., New York, USA) it is possible to show significant 
changes in actigraphically measured activity up to 6 h post dose with 
promethazine. This study collected data in short 10 sec epochs and pooled 
the data into 20 min bins. A further study [33] on antidepressants in healthy 
volunteers recorded activity in epochs of 30 sec and pooled the data into 12.5 
min bins. This study demonstrated a reduction in activity levels following 
dothiepin dosing and showed that actigraphy closely followed the time course 
of psychometric impairment. However, due to the stimulating influence of the 
tests this effect was only significant in overall activity levels. Both of these 
previous studies were conducted in conjunction with psychometric tests and 
the results suggested that actigraphy is able to measure the sedative effects 
of drugs in relation to decrements in psychomotor function. The time bins 
used in these two studies, however, differed from the current study whereby 
data was collected in 1 min epochs, being the default setting of the device, 
and pooled into 30 min bins. This was in order to differentiate between 
‘controlled’ activity during the 30 min test points and ‘spontaneous’ activity 
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between the test points. The reduction in ‘spontaneous’ activity levels during 
the 5 h period after LZP dosing closely followed the impairment observed in 
the psychometric tests confirming that actigraphy is able to detect a drug-
induced effect. 
 
Data need not only be calculated in activity counts, reduced daytime activity 
can also be interpreted as sleepiness or ‘sleep-like’ behaviour by using the 
propriety sleep analysis software algorithm to score each epoch as either 
sleep or wake. Various studies [24,28,29] have successfully used this method 
to calculate overall ‘sleep-like’ behaviour. As in the present study, no 
significant effect of treatment was found on the overall number of ‘sleep-like’ 
epochs during the 5 h period post dose, however, significance was found in 
the 30 min interval at 4 h post dose. This was during the half hour just prior to 
the 4.5 h test point which also showed the greatest impairment in the 
performance of the psychometric tests and the subjective rating of sedation in 
the LARS. 
 
LZP has been shown to alter sleep architecture as determined by PSG [35], 
by reducing sleep latency, number of awakenings, % Stage 1 sleep and REM, 
whilst increasing total sleep time and Stage 2 sleep. In the present study the 
actigraphic analysis of the sleep period revealed significant reductions in the 
activity levels at the beginning and end of the sleep period indicating more 
restful sleep which is consistent with the previous findings. The actigraphic 
sleep parameters confirm this improvement in sleep showing an increase in 
the actual sleep percent and the length of the sleep bouts, a reduction in the 
number of wake bouts and the fragmentation index. This clearly indicates that 
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the actigraphy data are consistent with previous PSG findings of the effect of 
LZP and provides a less expensive non-invasive alternative for detecting 
changes in sleep due to the effect of a drug. 
 
As psychoactive drugs have varied durations of efficacy, it is important to 
establish the maximum duration of impairment in order to provide safety data 
when prescribing. If a hypnotic taken to aid sleep has residual or hangover 
effects in the morning clearly this may be a safety hazard. Previous studies 
[18,19,22] have shown that actigraphy is useful in providing data on residual 
effects, by showing a reduction in activity levels following dosing. However, 
these data [18,19,22] were presented in large time blocks of 4 h or more. The 
present study shows that actigraphy is able to detect a significant reduction in 
activity in the waking hour immediately following the sleep period. This was 
confirmed by the psychomotor impairment observed in the morning following 
LZP compared to placebo. Although the LARS did not show that subjects 
taking LZP were more sedated in the morning, the results of the psychometric 
tests revealed that LZP had caused a sedating effect and impaired their 
cognitive ability. 
 
Similar results were obtained following a repeated dose of LZP. There was a 
significant reduction in activity in the 5 h period immediately following dosing, 
as well as a hangover effect the following morning. The actigraphic sleep 
showed a similar profile with the second dose of LZP again improving sleep, 
by reducing movement. This finding is in agreement with a previous study 
using repeated dosing [22]. 
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In conclusion, this study provides further evidence that actigraphy is sensitive 
not only to the sedating effects of a hypnotic drug as measured by a reduction 
in behavioural activity but also to the hangover effects of the drug the 
following morning. It also confirms that the actiwatch is able to detect the 
effects of a hypnotic on actigraphically measured sleep. Moreover this study, 
following the recommendation of Roehrs and colleagues [24], adds further 
evidence that actigraphy can provide a reliable and sensitive indication of the 
time course of action of psychoactive drugs. Studies using actigraphy to 
measure the effects of other psychoactive compounds and drug groups in 
both subject and patient populations both in the laboratory and in field studies 
will be necessary to further validate this method as a useful tool in 
psychopharmacology. 
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Table 1 Effect of LZP and placebo on actigraphic sleep parameters  
 
  Night 1 Night 2 
Variable  Placebo Lorazepam Placebo Lorazepam 
Actual Sleep Percent       88 ± 1       91 ± 1 *       89 ± 1       92 ± 1 * 
Actual Wake Time (mins)       56 ± 5       45 ± 5 *       53 ± 7       40 ± 7 * 
Number of Wake Bouts       28 ± 2       22 ± 2 *       27 ± 2       22 ± 2 
Number of Immobile Phases       41 ± 2       34 ± 2 *       40 ± 2       35 ± 2 
Percentage Time Immobile       88 ± 1       90 ± 1 *       87 ± 1       90 ± 1 ** 
Percentage Time Moving       12 ± 1       10 ± 1 *       13 ± 1       10 ± 1 ** 
Mean Activity Score       14 ± 2       11 ± 2 *       13 ± 2         9 ± 1 
Fragmentation Index       26 ± 2       21 ± 2 *       25 ± 3       21 ± 2 
Number of Minutes Moving       57 ± 5       47 ± 4 *       61 ± 5       47 ± 3 ** 
Total Activity Score   6574 ± 720   5132 ± 777 *   6281 ± 1058   4404 ± 419 
Sleep Efficiency Percentage       86 ± 1       90 ± 1       87 ± 2       91 ± 1 
Number of 1 min Immobile Minutes         6 ± 5         4 ± 4         5 ± 1         4 ± 1 
Mean Length Immobility (mins)       11 ± 1       14 ± 1 **       11 ± 1       13 ± 1 
Number of Immobile Minutes     413 ± 5      429 ± 4     411 ± 6     430 ± 3 
Percentage of 1 min Immobile Minutes       14 ± 2       11 ± 1       12 ± 2       12 ± 2 
Mean Sleep Bout Time (mins)       17 ± 1       23 ± 2 **       18 ± 2       24 ± 2 
Mean Wake Bout Time (mins)        2 ± 0.1         2 ± 0.1         2 ± 0.2         2 ± 0.1 
Mean Activity Score in Active Periods    111 ± 7     104 ± 10       96 ± 7       93 ± 7 
Wake Movement Average    186 ± 13     183 ± 12     167 ± 12     156 ± 10 
Sleep Latency (mins)        9 ± 2         4 ± 1         8 ± 2         3 ± 1 
     
Data are provided as sleep parameters calculated with the Sleepwatch Algorithm and 
presented as mean ± SEM (n=21)  
* P < 0.05, ** P < 0.01 versus corresponding placebo 
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Figure legends 
 
Figure 1  
Time course of effect of placebo () and LZP 2.5 mg () on activity as 
measured by actigraphy (# = psychometric test point, controlled activity) on 
(a) Day 2 and (b) Day 3. 
*P< 0.05, ** P < 0.01, *** P<0.0001 compared to corresponding placebo 
Data are presented as mean ± SEM (n=21)  
 
 
Figure 2  
Time course of effect of placebo () and LZP 2.5 mg () on activity during 
sleep on (a) Night 2 and (b) Night 3 as measured by actigraphy, 5 h post dose 
corresponds to 23:00 h. 
*P< 0.05, ** P < 0.01 compared to corresponding placebo 
Data are presented as mean ± SEM (n=21)  
 
 
Figure 3 
Time course of effect of placebo () and LZP 2.5 mg () on ‘sleep-like’ 
minutes on Day 2 during ‘spontaneous’ activity. 
* P = 0.0517 compared to corresponding placebo 
Data are presented as mean ± SEM (n=21)  
 
 
Figure 4  
Time course of effect of placebo () and LZP 2.5 mg () on (a) sedation 
component of LARS, (b) total reaction time of CRT (c) reaction time of CTT 
and (d) tracking error of  CTT. 
* P < 0.05, ** P < 0.01 compared to corresponding placebo 
Data are presented as mean ± SEM (n=21)  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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